The estimated Net Worth of Karen Krasney is at least 431 千$ dollars as of 3 November 2022. Ms Krasney owns over 18,932 units of Capricor Therapeutics Inc stock worth over 83,796$ and over the last 10 years she sold CAPR stock worth over 0$. In addition, she makes 346,750$ as Exec. VP、 Gen. Counsel & Sec. at Capricor Therapeutics Inc.
Ms has made over 4 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 18,932 units of CAPR stock worth 26,315$ on 3 November 2022.
The largest trade she's ever made was exercising 18,932 units of Capricor Therapeutics Inc stock on 3 November 2022 worth over 26,315$. On average, Ms trades about 2,277 units every 190 days since 2015. As of 3 November 2022 she still owns at least 20,047 units of Capricor Therapeutics Inc stock.
You can see the complete history of Ms Krasney stock trades at the bottom of the page.
Karen G. Krasney is the Exec. VP, Gen. Counsel & Sec. at Capricor Therapeutics Inc.
As the Exec. VP、 Gen. Counsel & Sec. of Capricor Therapeutics Inc, the total compensation of Ms Krasney at Capricor Therapeutics Inc is 346,750$. There are no executives at Capricor Therapeutics Inc getting paid more.
Ms Krasney is 68, she's been the Exec. VP、 Gen. Counsel & Sec. of Capricor Therapeutics Inc since . There are 3 older and 13 younger executives at Capricor Therapeutics Inc. The oldest executive at Capricor Therapeutics Inc is Louis Grasmick, 90, who is the Independent Director.
Karen's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over 949,404,468$ worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth 18,843,106$ . The most active insiders traders include Sinai Medical Center Cedars、John Edward A.Edward St. Jo...、Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of 494,068$. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth 47,260$.
capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has
Capricor Therapeutics Inc executives and other stock owners filed with the SEC include: